StockData
ProKidney Corp. logo

ProKidney Corp. (PROK) stock

PROKNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 12, 2026Score 5/30
$1.04−0.06 (-5.45%)

Close on Nov 18, 2026Market cap $314.42MP/E –Yield –

ProKidney free cash flow

Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.

ProKidney's free cash flow for the twelve months ending Jun 30, 2026 was -$159.73M. For fiscal 2025 it was -$135.31M. The highest annual figure on record is -$30.64M in fiscal 2020.

Annual free cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$135.31M–
FY2024Dec 31, 2024-$155.86M–
FY2023Dec 31, 2023-$124.27M–
FY2022Dec 31, 2022-$78.94M–
FY2021Dec 31, 2021-$55.49M–
FY2020Dec 31, 2020-$30.64M–

Quarterly free cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$44.21M–
Q1 FY2026Mar 31, 2026-$45.47M–
Q4 FY2025Dec 31, 2025-$38.27M–
Q3 FY2025Sep 30, 2025-$31.79M–
Q2 FY2025Jun 30, 2025-$34.53M–
Q1 FY2025Mar 31, 2025-$30.73M–
Q4 FY2024Dec 31, 2024-$49.68M–
Q3 FY2024Sep 30, 2024-$31.65M–
Q2 FY2024Jun 30, 2024-$38.93M–
Q1 FY2024Mar 31, 2024-$35.61M–
Q4 FY2023Dec 31, 2023-$26.96M–
Q3 FY2023Sep 30, 2023-$51.72M–
Q2 FY2023Jun 30, 2023-$18.62M–
Q1 FY2023Mar 31, 2023-$26.98M–
Q4 FY2022Dec 31, 2022-$16.07M–
Q3 FY2022Sep 30, 2022-$23.16M–
Q2 FY2022Jun 30, 2022-$23.41M–
Q1 FY2022Mar 31, 2022-$16.30M–
Q4 FY2021Dec 31, 2021-$13.53M–

More ProKidney figures

See a number that looks wrong?